Lexeo Therapeutics, Inc. (LXEO) Cash Flow Statement
Lexeo Therapeutics, Inc. (LXEO) generated -$88.4M of operating cash flow over the twelve months to 2026-06-30, spent $331000 on capital expenditure and had free cash flow of -$88.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXEOLexeo Therapeutics, Inc.Follow LXEO — free
—
Price chart with a free account
- Market cap
- 229.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -59.5 | -81.2 | -98.6 | -88.4 | |
| Capital expenditure | 0.1 | 0.5 | 0.4 | -0.3 | |
| Free cash flow | -59.6 | -81.6 | -99.0 | -88.7 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 3.0 | 12.5 | 12.1 | — |
USD millions · SEC XBRL
Lexeo Therapeutics, Inc. — questions
- What is Lexeo Therapeutics, Inc.'s operating cash flow?
- -$88.4M over the twelve months to 2026-06-30.
- How much does Lexeo Therapeutics, Inc. spend on capital expenditure?
- $331000 over the twelve months to 2026-06-30.
- What is Lexeo Therapeutics, Inc.'s free cash flow?
- -$88.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Lexeo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.